CA2683754A1 - Traitement du syndrome de down au moyen d'antagonistes des recepteurs des benzodiazepines - Google Patents

Traitement du syndrome de down au moyen d'antagonistes des recepteurs des benzodiazepines Download PDF

Info

Publication number
CA2683754A1
CA2683754A1 CA002683754A CA2683754A CA2683754A1 CA 2683754 A1 CA2683754 A1 CA 2683754A1 CA 002683754 A CA002683754 A CA 002683754A CA 2683754 A CA2683754 A CA 2683754A CA 2683754 A1 CA2683754 A1 CA 2683754A1
Authority
CA
Canada
Prior art keywords
composition
benzodiazepine
active pharmaceutical
pharmaceutical ingredient
flumazenil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002683754A
Other languages
English (en)
Inventor
Srinivas Rao
Jeffery J. Anderson
Jay D. Kranzler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cypress Bioscience Inc
Original Assignee
Cypress Biosciences, Inc.
Srinivas Rao
Jeffery J. Anderson
Jay D. Kranzler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cypress Biosciences, Inc., Srinivas Rao, Jeffery J. Anderson, Jay D. Kranzler filed Critical Cypress Biosciences, Inc.
Publication of CA2683754A1 publication Critical patent/CA2683754A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002683754A 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des recepteurs des benzodiazepines Abandoned CA2683754A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91125407P 2007-04-11 2007-04-11
US60/911,254 2007-04-11
PCT/US2008/060133 WO2008128116A1 (fr) 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des récepteurs des benzodiazépines

Publications (1)

Publication Number Publication Date
CA2683754A1 true CA2683754A1 (fr) 2008-10-23

Family

ID=39864354

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002683754A Abandoned CA2683754A1 (fr) 2007-04-11 2008-04-11 Traitement du syndrome de down au moyen d'antagonistes des recepteurs des benzodiazepines

Country Status (5)

Country Link
EP (1) EP2146576A4 (fr)
JP (1) JP2010523716A (fr)
AU (1) AU2008240148B2 (fr)
CA (1) CA2683754A1 (fr)
WO (1) WO2008128116A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012114342A1 (fr) 2011-02-23 2012-08-30 Coeruleus Ltd. Complexes de flumazénil, compositions les comprenant et leurs utilisations
US20220354807A1 (en) * 2019-09-30 2022-11-10 Xiamen University Use of valeric acid derivative in treatment of down's syndrome

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6297256B1 (en) * 1999-06-15 2001-10-02 Neurogen Corporation Aryl and heteroaryl substituted pyridino derivatives GABA brain receptor ligands
ATE350382T1 (de) * 2003-07-25 2007-01-15 Neurogen Corp Imidazopyrimidine und triazolopyrimidine: benzodiazepinrezeptorliganden
AU2006287378A1 (en) * 2005-09-07 2007-03-15 Braincells, Inc. Modulation of neurogenesis by HDac inhibition

Also Published As

Publication number Publication date
AU2008240148A1 (en) 2008-10-23
WO2008128116A1 (fr) 2008-10-23
EP2146576A4 (fr) 2013-01-16
JP2010523716A (ja) 2010-07-15
AU2008240148B2 (en) 2012-09-27
EP2146576A1 (fr) 2010-01-27

Similar Documents

Publication Publication Date Title
EP1272218B1 (fr) Composition pharmaceutique servant a traiter une douleur chronique aigue et/ou une douleur neurophatique ou des migraines
US20060122127A1 (en) Methods for reducing the side effects associated with mirtzapine treatment
WO2007087425A1 (fr) Procédés et compositions pour le traitement de la schizophrénie
US20080175903A1 (en) Treatment of anxiety with eszopiclone
CA2716757A1 (fr) Kit, composition, produit ou medicament pour le traitement de troubles cognitifs
US20100204205A1 (en) Tolerability of mirtazapine and a second active agent by using them in combination
AU2004204825A1 (en) Method of treating functional bowel disorders
JP2012232978A (ja) ４−｛３−［ｃｉｓ−ヘキサヒドロシクロペンタ［ｃ］ピロール−２（１Ｈ）−イル］プロポキシ｝ベンズアミドとアセチルコリンエステラーゼ阻害剤との新規な組み合わせ、及びそれを含む医薬組成物
KR20140146217A (ko) 파킨슨병을 치료하는 방법
EA017915B1 (ru) Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении
US20090275562A1 (en) Tolerability of mirtazapine and a second active by using them in combination
AU2006306547A1 (en) Tricyclic compounds useful as oxytocin receptor agonists
AU2008240148B2 (en) Treatment of down syndrome with benzodiazepine receptor antagonists
US20080096870A1 (en) Methods and Materials for Treating Mental Illness
US20090270373A1 (en) Treatment of down syndrom with benzodiazepine receptor antagonists
US9333208B2 (en) HCN inhibitors affecting ganglion cell function and visual function
TWI457123B (zh) ４－｛３－［順式－六氫環戊并［ｃ］吡咯－２（１ｈ）－基］丙氧基｝苯甲醯胺與ｎｍｄａ受體拮抗劑之新結合及包含彼等之醫藥組合物
RU2277096C2 (ru) Средства против слабоумия, содержащие производное 2-арил-8-оксодигидропурина в качестве активного ингредиента
WO2013130422A1 (fr) Compositions et méthodes de traitement de maladies mitochondriales
WO2013036224A1 (fr) Utilisation de 1h-quinazoline-2,4-diones dans la prévention ou le traitement de l'épilepsie photosensible
US20150051246A1 (en) Treatment of Cognitive Impairment with Combination Therapy
US20130090346A1 (en) Use of 1H-quinazoline-2,4-diones
US20170027949A1 (en) ASSOCIATION BETWEEN 8-CYCLOPROPYL-3-[2-(3-FLUOROPHENYL)ETHYL]-7,8-DIHYDRO-3H-[1,3]OXAZINO[6,5-g][1,2,3]BENZOTRIAZINE-4,9-DIONE AND AN ACETYLCHOLINESTERASE INHIBITOR, AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
US20100227844A1 (en) Cannabinoid-1 receptor modulators useful for the treatment of alzheimer's disease
JP2004292316A (ja) アルツハイマー型痴呆の日常生活動作能力改善剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead

Effective date: 20130805